Connect with us

Health

Drug Repurposing in Cancer Treatment: Emerging Strategies and Promising Developments

Published

on

Drug Repurposing in Cancer Treatment

Cancer continues to be one of the leading causes of death globally, with millions of new diagnoses each year. The conventional process of developing new cancer drugs is notoriously slow and costly, often requiring more than a decade and billions of dollars to reach patients. In response, drug repurposing, also called drug repositioning, has gained significant attention as a practical alternative. This strategy finds new anticancer applications for medications already approved for other medical conditions. Because these drugs have established safety records, known dosing guidelines, and existing production methods, repurposing can dramatically shorten development timelines and lower financial barriers compared with creating entirely new compounds. Organizations focused on innovative and integrative oncology approaches, such as Sanare Lab, offer valuable insights and resources for exploring experimental protocols in this rapidly evolving field.

One especially interesting avenue within drug repurposing is methylene blue cancer research. This compound, long used as a dye and as a treatment for methemoglobinemia, is now under investigation for possible anticancer effects. Researchers have examined methylene blue in photodynamic therapy, where it serves as a photosensitizer. When activated by specific wavelengths of light, it generates reactive oxygen species that can damage and kill cancer cells. Laboratory and animal studies have shown reductions in tumor volume in models of colorectal cancer, breast cancer, and melanoma, particularly when combined with other treatment approaches. These findings illustrate how a familiar, inexpensive compound might provide new ways to target resistant or difficult-to-treat tumors.

Why Drug Repurposing Matters in Oncology

The main advantage of repurposing lies in its efficiency. Traditional drug discovery begins with identifying a new molecule, followed by years of laboratory testing, animal studies, and multi-phase human trials to confirm both safety and effectiveness. Repurposed drugs skip much of this early work because regulators have already approved them for their original use. Investigators can therefore move more quickly to testing whether the drug works against cancer, often starting directly in mid- or late-stage clinical trials.

Cost is another critical factor. The failure rate in new oncology drug development frequently exceeds ninety percent, driving up expenses that are eventually reflected in treatment prices. Many repurposed candidates are off-patent generics, which means they can be produced and distributed at a fraction of the cost of branded medicines. With cancer rates expected to keep rising worldwide, especially in low- and middle-income countries, affordable options derived from existing drugs could help close gaps in access to effective care.

Well-Known Examples of Repurposed Drugs in Cancer

Drug repurposing already has several important successes in oncology. Thalidomide, originally marketed as a sedative and later withdrawn because of severe birth defects, was rediscovered in the late 1990s for multiple myeloma. Its ability to block new blood vessel formation in tumors made it a valuable addition to treatment regimens, and it remains widely used today, frequently combined with other agents.

See also  UK Confirms 36 Possible Cases of Baby Formula Intoxication Amid Global Recalls

All-trans retinoic acid, first studied for skin conditions, transformed outcomes in acute promyelocytic leukemia by prompting malignant cells to mature into normal ones. When paired with arsenic trioxide, another agent with a long history in traditional medicine, the combination now achieves very high remission rates in this once-deadly subtype of leukemia.

Metformin, the most commonly prescribed medication for type 2 diabetes, has attracted attention after population studies showed lower cancer rates among diabetic patients taking it. The drug appears to interfere with energy metabolism in cancer cells by activating a key regulatory pathway that slows uncontrolled growth. Multiple clinical trials have tested metformin as an add-on to standard chemotherapy or radiation in breast, prostate, colorectal, and other cancers, with some studies reporting improved survival or reduced recurrence.

Statins, best known for lowering cholesterol, have also been evaluated for anticancer effects. By blocking an enzyme involved in cholesterol synthesis, they disrupt signaling pathways that cancer cells use to grow and spread. Large observational studies have linked statin use to modestly reduced risk of certain cancers, and ongoing research continues to explore their role as adjunctive therapy.

Other candidates include antiparasitic agents such as mebendazole, which interfere with the structural framework cancer cells need to divide, and the anticonvulsant valproic acid, which modifies gene expression by inhibiting enzymes that control DNA packaging. Both have shown activity in laboratory models of colorectal, brain, and pancreatic cancers, and early human studies are underway.

Spotlight on Methylene Blue in Cancer Research

Returning to methylene blue, this compound continues to generate interest because of its diverse biological effects. Beyond its role in photodynamic therapy, methylene blue can influence cancer cell metabolism. Many tumors depend heavily on glycolysis for energy production even when oxygen is available, a phenomenon known as the Warburg effect. Methylene blue appears to disrupt this altered metabolism, potentially starving cancer cells of fuel. In preclinical models of ovarian cancer, particularly those resistant to platinum-based chemotherapy, methylene blue slowed tumor progression more effectively than standard drugs in some experiments.

When used in photodynamic therapy, methylene blue tends to concentrate in mitochondria, the energy-producing structures inside cells. Light exposure then triggers the release of damaging oxygen radicals, leading to cell death through apoptosis. Systematic reviews of animal studies have reported consistent tumor shrinkage across several cancer types, including breast carcinoma and skin melanoma, often with low toxicity at the doses tested.

See also  European Environment Agency Links Pollution to Rising Mental Health Risks

Methylene blue may also improve tumor oxygenation, which could make radiotherapy more effective. Poorly oxygenated regions within solid tumors are notoriously resistant to radiation, so any agent that increases oxygen availability has therapeutic potential. In addition, surgeons sometimes use methylene blue injections to map sentinel lymph nodes during breast cancer operations, helping to identify the first nodes where cancer is most likely to spread.

Despite these encouraging signals, methylene blue remains experimental for most cancer applications. While side effects are generally mild at therapeutic doses, interactions with certain medications require careful monitoring. Large, well-controlled clinical trials are still needed to determine whether the promising laboratory and early human data translate into meaningful benefits for patients.

Remaining Challenges and the Path Forward

Drug repurposing is not without obstacles. Because many candidate drugs are generic, pharmaceutical companies have limited financial incentive to fund expensive trials for new indications. Regulatory agencies sometimes require nearly as much evidence for a repurposed use as for a completely novel drug, which can slow progress. Off-label prescribing also raises questions about informed consent and standardized protocols when robust data are lacking.

Collaborative efforts are helping to address these barriers. Networks of researchers, clinicians, and advocacy groups are systematically reviewing existing drugs for anticancer potential, prioritizing those with the strongest preclinical rationale, and pushing for well-designed trials. Advances in computational biology allow scientists to screen thousands of compounds against cancer-related targets much faster than before, narrowing the list of drugs worth testing in the laboratory or clinic.

Looking ahead, combination strategies are likely to dominate. Pairing repurposed agents with immunotherapy, targeted therapies, or conventional chemotherapy could produce synergistic effects greater than any single treatment alone. Personalized approaches that match specific drugs to the molecular features of an individual’s tumor will further refine their use.

In summary, drug repurposing offers a realistic and increasingly important strategy for improving cancer care. From established successes like thalidomide and metformin to emerging candidates such as methylene blue, the field demonstrates that familiar medicines can sometimes deliver unexpected benefits against one of medicine’s toughest challenges. Sustained investment in rigorous clinical research and broader collaboration will determine how much further this approach can take us toward more effective, accessible treatments for patients everywhere.

Health

Taking the Stairs Could Cut Risk of Heart Disease Death, Study Finds

Published

on

Taking the stairs instead of using a lift could significantly reduce the risk of cardiovascular disease and premature death, according to a major study examining the health benefits of regular stair climbing.

Researchers from the University of East Anglia and Norfolk and Norwich University Hospital found that people who regularly climbed stairs had a 39 percent lower risk of dying from cardiovascular disease than those who rarely used stairs. They also had a 24 percent lower risk of death from any cause.

The study found that regular stair climbing was also associated with a lower risk of developing serious cardiovascular conditions, including heart attacks, strokes and heart failure.

The research team analysed health data from more than 480,000 people aged between 35 and 84. The findings were based on nine high-quality studies, with participants followed for a median period of 14 years.

Vassilios Vassiliou of Norwich Medical School at the University of East Anglia said stair climbing was a practical way to add physical activity to everyday routines. He described it as an activity that is often overlooked despite being easy to perform without special equipment or facilities.

Unlike structured exercise at a gym, climbing stairs can be included naturally in daily activities at home, at work or while travelling. Sophie Paddock, also from Norwich Medical School, said the activity could be particularly useful for people who have limited time or do not have convenient access to exercise facilities.

The researchers said even short periods of stair climbing several times a week could provide measurable health benefits. The activity can improve cardiorespiratory fitness and help lower cholesterol, both of which are linked to better cardiovascular health.

See also  Papua New Guinea Launches Emergency Polio Response After New Cases Detected

The amount of stair climbing also appeared to matter. Some of the studies reviewed by the researchers found that people who climbed more stairs generally experienced greater health benefits. However, even smaller amounts of activity were associated with positive changes.

The findings are particularly relevant as more than a quarter of adults worldwide do not meet recommended levels of physical activity. The researchers said encouraging simple forms of movement in everyday environments could help address this problem.

Workplaces, homes and public buildings could all play a role by making stair use easier and more appealing. Choosing stairs over lifts when possible may provide an accessible form of physical activity without requiring people to set aside additional time for a workout.

The findings were presented at a scientific congress of the European Society of Cardiology. Researchers said the results highlight how small changes in daily routines can contribute to better long-term health and may help reduce the burden of cardiovascular disease.

Continue Reading

Health

Children Who Play Alone May Still Feel Happy and Connected, Study Finds

Published

on

Children who spend much of their school day playing alone may not necessarily be lonely or unhappy, according to a new study from researchers at the University of Georgia in the United States.

The research suggests that some children simply enjoy their own company while maintaining satisfying friendships and a sense of belonging among their classmates. Researchers say the key factor may not be how often a child chooses to be alone, but whether they still feel connected to others.

The study involved 473 children aged between nine and 11 at several elementary schools in Georgia. Participants were asked to identify classmates who often played alone despite getting along with other students. They also answered questions about the importance they placed on belonging and their satisfaction with friendships and relationships within their classes.

Researchers found a clear difference between children who preferred solitude while still valuing social connections and those who placed little importance on belonging to a peer group.

Children who enjoyed spending time alone but considered belonging important generally reported being satisfied with both their close friendships and wider relationships at school. Researchers said these children may accept enough invitations to remain socially connected while choosing to spend some of their free time alone.

Rachael Pfanz, the study’s corresponding author and an elementary school psychologist, said these children can prefer doing their own activities without having difficulty getting along with classmates.

The findings were different for children who did not consider belonging important. They were more likely to report weaker relationships with friends and classmates.

See also  Denmark to Compensate Greenlandic Women Subjected to Forced Birth Control

Researchers warned that repeatedly turning down invitations can eventually affect a child’s social opportunities. Classmates may stop asking them to join activities, potentially leaving them with fewer chances to develop or maintain friendships.

Michele Lease, a professor of educational psychology at the University of Georgia and a co-author of the study, compared social interaction with other activities that benefit people even when they may not always feel like participating.

The researchers said adults should avoid assuming that every child who plays alone needs to be encouraged to join a large group immediately. Pressuring a child into a busy activity could make the situation uncomfortable rather than helping them build connections.

Instead, adults could introduce children to smaller groups or classmates who share similar interests. A child who enjoys drawing, reading, building or another individual activity may find it easier to connect with peers who have the same interests.

Pfanz said joining a large playground game, such as soccer, may feel overwhelming for a child who already prefers playing alone.

The researchers said the findings are particularly relevant to fourth- and fifth-grade students, a period when friendship groups become more established and children become better at recognising whether classmates are choosing solitude or experiencing social exclusion.

The study suggests that solitude itself should not automatically be viewed as a problem. What may matter more is whether children have meaningful relationships and continue to feel that they belong.

Continue Reading

Health

Good Vascular Health in Midlife Linked to Longer Dementia-Free Life

Published

on

Maintaining healthy blood pressure, avoiding diabetes and not smoking during middle age may help people spend more years of their lives free from dementia, according to new research.

A study of more than 12,000 participants found that people without the three major vascular risk factors between the ages of 48 and 68 could gain nearly 13 additional years without developing dementia compared with those who had all three conditions.

The findings highlight the importance of managing cardiovascular health during midlife as researchers continue to examine ways to reduce the growing global burden of dementia.

Dementia affects millions of people worldwide, with about 10 million new cases diagnosed each year, according to the World Health Organization. The number of people living with the condition is expected to exceed 150 million by 2050.

Researchers are increasingly examining factors that can be changed earlier in life, including smoking, high blood pressure and diabetes, because these conditions can affect blood vessels and contribute to problems affecting the brain.

The study, published in Neurology Open Access, defined good vascular health as having no diabetes, hypertension or smoking history during middle age.

Researchers found that participants with all three risk factors faced almost three times the risk of developing dementia compared with people who had none of them.

At age 55, people with no vascular risk factors could expect to live an average of 30 more years without dementia. Those with one risk factor had an average of 26 dementia-free years, while people with two had about 21 years.

See also  WHO Urges Global Overhaul of School Food to Combat Childhood Obesity

Participants with all three risk factors could expect just over 17 years without dementia. The difference between those with no risk factors and those with all three was therefore about 13 years.

The researchers said the results suggest that protecting vascular health during midlife could have a substantial effect on brain health later in life.

“Our findings argue that people need to actively avert these factors in midlife as a strategy for preserving brain health for more than a decade,” said senior investigator Josef Coresh.

The study also identified differences between men and women. Women generally had more dementia-free years than men across the groups. Among participants with all three risk factors, women averaged about 18 years without dementia, compared with 16 years for men.

The researchers said the findings reinforce the importance of preventing or managing high blood pressure and diabetes and avoiding smoking during middle age.

Coresh said the results could encourage people to pay closer attention to their vascular health from their late 40s onward, potentially helping them maintain cognitive health for longer as they age.

Continue Reading

Trending